Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Tel Hashomer Medical Research Infrastructure and Services Ltd. has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct examiners and 6 distinct art units. This broad distribution reflects a diverse range of research and development activities being prosecuted simultaneously. The involvement of 6 distinct art units indicates that each pending application falls into a different technical classification, suggesting a wide-reaching intellectual property strategy.
VILLECCO, JOHN M is identified as the busiest examiner, though he only manages 1 pending office action. With 6 distinct examiners each handling a portion of the 6 pending office actions, the workload is spread across the individuals involved. This means that no single examiner's decisions will disproportionately affect the overall portfolio. However, managing 6 distinct examiners requires a significant amount of coordination and attention to detail for each individual case.
For a practitioner, managing 6 pending office actions across 6 distinct art units requires a high level of versatility. Since VILLECCO, JOHN M only holds 1 pending action, the prosecution strategy must be tailored to the specific standards of each individual. This variety requires the practitioner to stay informed about the practices of 6 distinct art units. The lack of concentration in any single unit or examiner highlights the breadth of the company's current patent activities.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VILLECCO, JOHN M | 1 | 64.5% | +9.5% |
| BECKHARDT, LYNDSEY MARIE | 1 | 27.8% | +48.0% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.3% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| FREDRICKSON, COURTNEY B | 1 | 75.4% | +29.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270852 | AURICULAR RECONSTRUCTION USING 3D PRINTED AUTOLOGOUS CARTILAGE TISSUE | BECKHARDT, LYNDSEY MARIE | 28d overdue |
| 18256747 | COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS | ROZOF, TIMOTHY R | 5d |
| 18223106 | METHOD AND SYSTEM FOR IMAGING EYE BLOOD VESSELS | VILLECCO, JOHN M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270852 | AURICULAR RECONSTRUCTION USING 3D PRINTED AUTOLOGOUS CARTILAGE TISSUE | BECKHARDT, LYNDSEY MARIE | 28d overdue |
| 18256747 | COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS | ROZOF, TIMOTHY R | 5d |
| 17391227 | METHOD FOR DELIVERY OF COMPOSITIONS TO THE EYE | FREDRICKSON, COURTNEY B | 39d |
| 17430072 | DIAGNOSIS AND TREATMENT OF MEDULLOBLASTOMA | PERSONS, JENNA L | — |
| Art Unit | Apps |
|---|---|
| 2671 | 1 |
| 1613 | 1 |
| 1625 | 1 |
| 1658 | 1 |
| 1637 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18223106 | METHOD AND SYSTEM FOR IMAGING EYE BLOOD VESSELS | VILLECCO, JOHN M | 2671 | §102§103 | Non-Final OA | — | Pending | Jul 18, 2023 |
| 18270852 | AURICULAR RECONSTRUCTION USING 3D PRINTED AUTOLOGOUS CARTILAGE TISSUE | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112 | Final Rejection | 28d overdue | Pending | Jul 04, 2023 |
| 18256747 | COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS | ROZOF, TIMOTHY R | 1625 | §101§102 | Final Rejection | 5d | Pending | Jun 09, 2023 |
| 17989817 | TARGETING G3BP AGGREGATION TO PREVENT NEURODEGENERATION | STEELE, AMBER D | 1658 | §102§103§112DP | Final Rejection | 51d overdue | Pending | Nov 18, 2022 |
| 17430072 | DIAGNOSIS AND TREATMENT OF MEDULLOBLASTOMA | PERSONS, JENNA L | 1637 | §103 | Final Rejection | — | Pending | Aug 11, 2021 |
| 17391227 | METHOD FOR DELIVERY OF COMPOSITIONS TO THE EYE | FREDRICKSON, COURTNEY B | 3783 | §112 | Non-Final OA | 39d | Pending | Aug 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTel Hashomer Medical Research Infrastructure and Services Ltd. has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
John M Villecco has the most, with 1 of Tel Hashomer Medical Research Infrastructure and Services Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
